Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
39results about How to "Improve in vivo activity" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Methods and compositions for modulating cell proliferation and cell death
InactiveUS6599912B1Enhance in vitroImprove in vivo activityBiocidePeptide/protein ingredientsAnticarcinogenTopoisomerase-II Inhibitor
Methods and compositions for modulating the FGF effect on the sensitivity of malignant and normal cells to anticancer agents are provided. In particular, methods and compositions for inhibiting FGF-induced resistance to a broad spectrum of anticancer agents in solid and soft-tissue tumors, metastatic lesions, leukemia and lymphoma are provided. Preferably, the compositions include at least one FGF inhibitor in combination with a cytotoxic agents, e.g., antimicrotubule agents, topoisomerase I inhibitors, topoisomerase II inhibitors, antimetabolites, mitotic inhibitors, alkylating agents, intercalating agents, agents capable of interfering with a signal transduction pathway (e.g., g., a protein kinase C inhibitor, e.g., an anti-hormone, e.g., an antibody against growth factor receptors), an agent that promotes apoptosis and / or necrosis, and interferon, an interleukin, a tumor necrosis factor, and radiation. In other embodiments, methods and composition for protecting a cell in a subject, from one or more of killing, inhibition of growth or division or other damage caused, e.g., by a cytotoxic agent, are provided. Preferably, the method includes: administering, to the subject, an effective amount of at least one FGF agonist, thereby treating the cell, e.g., protecting or reducing the damage to the dividing cell from said cytotoxic agent.
Owner:AU JESSIE L S +1
Fusion protein having the enhanced in vivo activity of erythropoietin
InactiveUS20090221037A1High activityImprove in vivo activitySugar derivativesAntibody mimetics/scaffoldsΒ subunitRed blood cell
The present invention relates to a fusion protein in which a carboxy terminal of human erythropoietin (EPO) is fused with a carboxy terminal peptide fragment of β subunit of human chorionic gonadotropin (HCG), to DNA encoding the fusion protein, and to a method for preparation of the fusion protein. The fusion protein has the enhanced in vivo activity of erythropoietin.
Owner:CJ HEALTHCARE CORP
Glycoprotein synthesis and remodeling by enzymatic transglycosylation
ActiveUS7807405B2Prolonged half-life-timeLess immunogenicVirus peptidesPeptide preparation methodsHalf-lifeGlycopeptide
A chemoenzymatic method for the preparation of a homogeneous glycoprotein or glycopeptide, including (a) providing an acceptor selected from the group consisting of GlcNAc-protein and GlcNAc-peptide; and (b) reacting the acceptor with a donor substrate including an activated oligosaccharide moiety, in the presence of a catalyst comprising endoglycosidase (ENGase), to transfer the oligosaccharide moiety to the acceptor and yield the homogeneous glycoprotein or glycopeptide. The donor substrate includes, in a specific implementation, a synthetic oligosaccharide oxazoline. A related method of glycoprotein or glycopeptide remodeling with a predetermined natural N-glycan or a tailor-made oligosaccharide moiety, and a method of remodeling an antibody including a heterogeneous sugar chain, are also described. The disclosed methodology enables glycoprotein drugs to be modified for prolonged half-life in vivo, reduced immunogenicity, and enhanced in vivo activity, and for targeting and drug delivery.
Owner:UNIV OF MARYLAND
Fusion protein having the enhanced in vivo activity of erythropoietin
InactiveUS8008454B2Improve in vivo activityExtended half-lifeSugar derivativesAntibody mimetics/scaffoldsΒ subunitDna encoding
The present invention relates to a fusion protein in which a carboxy terminal of human erythropoietin (EPO) is fused with a carboxy terminal peptide fragment of β subunit of human chorionic gonadotropin (HCG), to DNA encoding the fusion protein, and to a method for preparation of the fusion protein. The fusion protein has the enhanced in vivo activity of erythropoietin.
Owner:CJ HEALTHCARE CORP
Glycoprotein synthesis and remodeling by enzymatic transglycosylation
ActiveUS20080138855A1Prolonged half-life-timeLess immunogenicImmunoglobulins against animals/humansDepsipeptidesHalf-lifeGlycopeptide
A chemoenzymatic method for the preparation of a homogeneous glycoprotein or glycopeptide, including (a) providing an acceptor selected from the group consisting of GlcNAc-protein and GlcNAc-peptide; and (b) reacting the acceptor with a donor substrate including an activated oligosaccharide moiety, in the presence of a catalyst comprising endoglycosidase (ENGase), to transfer the oligosaccharide moiety to the acceptor and yield the homogeneous glycoprotein or glycopeptide. The donor substrate includes, in a specific implementation, a synthetic oligosaccharide oxazoline. A related method of glycoprotein or glycopeptide remodeling with a predetermined natural N-glycan or a tailor-made oligosaccharide moiety, and a method of remodeling an antibody including a heterogeneous sugar chain, are also described. The disclosed methodology enables glycoprotein drugs to be modified for prolonged half-life in vivo, reduced immunogenicity, and enhanced in vivo activity, and for targeting and drug delivery.
Owner:UNIV OF MARYLAND BALTIMORE
Long-Acting Peptide Analogs
ActiveUS20140155329A1Longer in vivo half-lifeImprove in vivo activityPeptide/protein ingredientsCalcitoninsCrystallographyIn vivo
Long-acting agonistic analogs for CLR / RAMP receptors are provided that have an extended half-live in vivo.
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV
2-sulfo-4-amino-1-naphthol derivative and preparation method and application thereof
InactiveCN102766103AImprove in vivo activityLow cytotoxicityOrganic chemistryAntineoplastic agentsSolventLow toxicity
The invention belongs to the field of pharmaceutical chemicals, and in particular relates to a 2-sulfo-4-amino-1-naphthol derivative and pharmaceutically acceptable salt thereof, a solvate of the derivative, and a solvate of the pharmaceutically acceptable salt. The invention also relates to a preparation method, a medical composition and application of the 2-sulfo-4-amino-1-naphthol derivative. The 2-sulfo-4-amino-1-naphthol derivative has a good tyrosine kinase inhibiting effect and low toxicity and has great significance for the clinical treatment of tumor.
Owner:QILU PHARMA +1
IgG-like long-acting immunological fusion protein and applications thereof
ActiveCN108623691AProlong biological half-lifeHigh affinityPeptide/protein ingredientsMetabolism disorderDiseaseAutoimmune disease
The invention discloses an IgG-like long-acting immunological fusion protein and applications thereof. The IgG-like long-acting immunological fusion protein comprises an effector molecule and an IgG antibody constant region, wherein the effector molecule is linked to the IgG antibody constant region through a linker peptide, the effector molecule is a protein capable of exerting physiological functions in vivo, and the IgG antibody constant region is a structure obtained by removing two heavy chain variable regions and two light chain variable regions from an IgG antibody. According to the present invention, the IgG-like immunological fusion protein can effectively prolong the biological half-life of the protein drug (effector molecule) under the premise of the ensuring of the high affinity to the targeting molecule and the good in vivo activity, is far better than the similar Fc immunological fusion protein, and can be used for the treatment of diabetes, tumors, autoimmune diseases, endocrine and various diseases.
Owner:BEIJING BIYANG BIOTECH
Fusion protein with reinforced erythrocytin activity in vivo
InactiveCN1421461AImprove in vivo activityThrombopoietinPeptide/protein ingredientsIn vivoC-terminus
Owner:CJ HEALTHCARE CORP
Nanoparticle as well as preparation method and application thereof
PendingCN114404391AEfficient releaseGood dispersionOrganic active ingredientsNanomedicineNanoparticleChemical compound
The invention relates to nanoparticles as well as a preparation method and application thereof, and belongs to the field of biological medicines. The nanoparticle comprises a compound as shown in a formula I and an auxiliary material. The nanoparticles can entrap nucleic acid, and have the advantages of low toxicity, high entrapment efficiency, good transfection effect and good bioavailability. The preparation method is simple to operate, low in cost, environment-friendly and beneficial to industrial production.
Owner:SHENZHEN LONGUIDE BIOPHARMA CORP
SS-carboline, dihydro-ß-carboline and tetrahydro-ß-carboline alkaloid derivatives and preparation methods same and use in aspects of preventing and treating plant viruses, fungicides and insecticides
The present invention relates to β-carboline, dihydro-β-carboline and tetrahydro-β-carboline alkaloid derivatives (I) and a method for preparing same and the use in the aspects of preventing and treating plant viruses, fungicides and insecticides. For the meaning of each group in formula (I) see the description. The β-carboline, dihydro-β-carboline and tetrahydro-β-carboline alkaloid derivatives of the present invention show a particularly ourstanding anti-plant virus activity, and also have fungicidal and insecticidal activities.
Owner:NANKAI UNIV +1
Alternaria alternata antagonistic actinomycete strain and application thereof
ActiveCN112592856AImprove in vivo activityLow costBiocideBacteriaBiotechnologyStreptomyces flavotricini
The invention discloses an alternaria alternata antagonistic actinomycete strain and an application thereof. The alternaria alternata antagonistic actinomycete strain is Streptomyces flavotricini F706, has a preservation name of the Streptomyces flavotricini F706, is preserved in the China Center for Type Culture Collection (CCTCC) at Luojia Mountain Wuhan University, Wuchang District, Wuhan City,Hubei Province on November 18, 2020, and has a preservation number of CCTCC No.M 2020755. A gene sequence of the alternaria alternata antagonistic actinomycete is a nucleotide sequence as shown in SEQ ID No.1.
Owner:GUIZHOU TOBACCO SCI RES INST
Medicine purpose of FXIa inhibitor compound or salt thereof
The invention belongs to the technical field of medicines, provides a medicine purpose of a FXIa inhibitor compound or salt thereof, and particularly relates to the purpose of the FXIa inhibitor compound or the salt thereof in preparation of medicines used for preventing and / or treating artery thrombi and venous thrombi.
Owner:SOUTH CHINA UNIV OF TECH +1
Fusion protein having enhanced in vivo activity of erythropoietin
ActiveUS7098318B2Prolong half-life in vivoHigh activityPeptide/protein ingredientsAntibody mimetics/scaffoldsHuman bodyHalf-life
The present invention relates to a fusion protein having enhanced in vivo activity of erythropoietin wherein a carboxy terminal peptide fragment of thrombopoietin is fused with the carboxy terminal of human erythropoietin. This fusion protein has highly enhanced in vivo half-life due to increased carbohydrate content without loss of the inherent activity of erythropoietin, and does not cause any antigenicity when applied to the human body.
Owner:CJ HEALTHCARE CORP
Medicinal composition with antioxidant activity and blood vessel and blood cleaning antioxidant and/or protective agent
InactiveCN102028895AImprove bioavailabilityNo irritationOrganic active ingredientsAntinoxious agentsSalvia miltiorrhizaGrape seed
The invention discloses a medicinal composition with antioxidant activity and a blood vessel and blood cleaning antioxidant and / or protective agent. The medicinal composition comprises the following raw materials in part by weight: 1 to 60 parts of grape seed, 10 to 200 parts of fresh apple, 5 to 80 parts of blueberry, 10 to 200 parts of piny flower, 5 to 60 parts of lemon, 20 to 80 parts of hawthorn, 5 to 50 parts of purple salvia miltiorrhiza, 5 to 50 parts of mulberry, 10 to 50 parts of Chinese wolfberry, 10 to 50 parts of codonopsis pilosula, 10 to 50 parts of rhodiola, 50 to 200 parts of glutinous rice bran; 5 to 50 parts of epimedium herb and 1 to 10 parts of zinc gluconate or ferrous gluconate or a mixture of the zinc gluconate and the ferrous gluconate. The invention has high bioavailability, is easily digested and absorbed, has no pessimal stimulation to gastrointestinal tracts, and can exert the effect of primary anthocyanidin extracted from different plants and plant seeds to the greatest degree.
Owner:张家港天乙传统医药研究院有限公司
Method of mass producing growth factor using adipose derived adult stem cells
InactiveUS20120065129A1Improve in vivo activityProduce growth factorCosmetic preparationsPeptide/protein ingredientsStem cell cultureAdult stem cell
Owner:PROSTEMICS +1
Maleimide-polyglutamic acid-aspartic acid polymer and composite thereof, preparation methods for maleimide-polyglutamic acid-aspartic acid polymer and composite thereof, and application of maleimide-polyglutamic acid-aspartic acid polymer and composite thereof
ActiveCN102617852AGood curative effectSmall toxicityPharmaceutical non-active ingredientsImidePolymer science
The invention discloses a maleimide-polyglutamic acid-aspartic acid polymer. The maleimide-polyglutamic acid-aspartic acid polymer is formed by the covalent bonding of a gamma-polyglutamic acid-aspartic acid polymer and amine compounds containing maleimide groups, wherein the bonding is realized by forming an amido bond between a free carboxyl group of the gamma-polyglutamic acid-aspartic acid polymer and amino groups on the amine compounds containing the maleimide groups under the coaction of a condensing agent and a catalyst. The invention also discloses a maleimide-polyglutamic acid-aspartic acid composite and a preparation method and application thereof. By coupling biological active molecules with a sulfydryl group, the stability and in-vivo activity of the maleimide-polyglutamic acid-aspartic acid polymer can be improved, and the in-vivo half life of the maleimide-polyglutamic acid-aspartic acid polymer can be prolonged; and meanwhile, the polymer which is coupled with targetingmolecules with the sulfydryl group and is combined with an anti-tumor medicine can become a polymer medicine with active targeting.
Owner:SHANGHAI INST OF BIOLOGICAL PROD CO LTD
Nanoparticle containing 5-methylpyrimidine-2, 4 (1H, 3H)-diketone derivative and preparation method and application thereof
PendingCN114601922AEfficient releaseAchieve therapeutic effectPowder deliveryOrganic active ingredientsDiketoneNanoparticle
The invention relates to nanoparticles as well as a preparation method and application thereof, and belongs to the field of biological medicines. The nanoparticle comprises a 5-methylpyrimidine-2, 4 (1H, 3H)-diketone derivative and an auxiliary material. The nanoparticles can entrap nucleic acid, and have the advantages of low toxicity, high entrapment efficiency, good transfection effect and good bioavailability. The preparation method is simple to operate, low in cost, environment-friendly and beneficial to industrial production.
Owner:SHENZHEN LONGUIDE BIOPHARMA CORP
Anthrax toxin receptor CMG2 and human serum albumin fused protein
ActiveCN105237640AImprove in vivo activityHigh affinityFungiPeptide preparation methodsAnthrax toxin receptorsHalf-life
The invention discloses a fused protein. The first part of the fused protein is recombinant anthrax toxin receptor CMG2, the second part is recombinant human serum albumin, the first part and the second part are connected by a linker peptide, the half-life in vivo of the fused protein is increased by nearly 20 times compared with the recombinant anthrax toxin receptor CMG2. Also, the fused protein has very good in vivo activity, and can fully protect toxin attacked experimental animals.
Owner:INST OF BIOENG ACAD OF MILITARY MEDICAL SCI OF THE CHINESE
Hasylated polypeptides, especially hasylated erythropoietin
InactiveCN101580547AImprove biostabilityImprove biological activityCosmetic preparationsPowder deliveryCarbohydrate moietyThioether
The present invention relates to hydroxyalkylstarch (HAS)-polypeptide-conjugate (HAS-polypeptide) comprising one or more HAS moecules, wherein each HAS is conjugated to the polypeptide via a carbohydrate moiety or a thioether as well as to methods for the production thereof. In a preferred embodiment, the polypeptide is erythropoietin (EPO).
Owner:FRESENIUS KABI DEUT GMBH
Maleimide-polyglutamic acid-aspartic acid polymer and composite thereof, preparation methods for maleimide-polyglutamic acid-aspartic acid polymer and composite thereof, and application of maleimide-polyglutamic acid-aspartic acid polymer and composite thereof
ActiveCN102617852BGood curative effectSmall toxicityPharmaceutical non-active ingredientsImidePolymer science
Owner:SHANGHAI INST OF BIOLOGICAL PROD CO LTD
Polysaccharide modified MBG scaffold, tissue repair scaffold, and preparation method and application thereof
InactiveCN109276763AImprove biological activityImprove structural propertiesTissue regenerationProsthesisTissue repairHigh activity
The invention relates to the field of a biological medicine material, and concretely provides a polysaccharide modified MBG scaffold, a tissue repair scaffold, and a preparation method and applicationthereof. The polysaccharide modified MBG scaffold provided by the invention comprises an MBG scaffold and a polysaccharide derivative loaded on the MBG scaffold, wherein the MBG scaffold has excellent biological activity and structure features; the polysaccharide derivative is used for performing polysaccharide modification on MBG; the obtained polysaccharide modified MBG scaffold can delay the release speed of growth factors in the material; and the high-activity release of the growth factors can be realized. The tissue repair scaffold, the preparation method and the application provided bythe invention achieve the advantage of the polysaccharide modified MBG scaffold; and the effects of slowly releasing the growth factors and repairing tissues can be achieved.
Owner:SHENZHEN INST OF ADVANCED TECH
IL-17 antibody
ActiveCN107236041AImprove thermal stabilityHigh affinityAntipyreticAnalgesicsCurative effectThermal stability
The invention relates to an IL-17 antibody, and belongs to the field of biomedicine. The IL-17 antibody comprises a heavy chain and a light chain, wherein the heavy chain and the light chain respectively comprise variable regions and constant regions; the sequence of the heavy chain variable regions comprises hypervariable regions HCDR1, HCDR2 and HCDR3 in turn; and the sequence of the light chain variable regions comprises hypervariable regions LCDR1, LCDR2 and LCDR3 in turn. The invention has the following advantage: The IL-17 antibody is an antibody which is high in thermal stability and simultaneously has high affinity, high inhibition activity and a curative effect.
Owner:STAIDSON BEIJING BIOPHARMACEUTICALS CO LTD
igg-like long-acting immune fusion protein and its application
ActiveCN108623691BProlong biological half-lifeHigh affinityPeptide/protein ingredientsMetabolism disorderAntiendomysial antibodiesAutoimmune disease
Owner:BEIJING BIYANG BIOTECH
Compositions and methods for inhibiting T cell exhaustion
PendingCN111727045AStrong in vivo activityImprove in vivo activityPolypeptide with localisation/targeting motifImmunoglobulin superfamilyAntigen receptorTransmissible disease
The present invention relates to T cell compositions and methods of using the same in the context of therapy and treatment. In particular, the invention provides T cells that are modified (e.g., genetically and / or functionally) to maintain functionality under conditions in which unmodified T cells display exhaustion. Compositions and methods disclosed herein find use in preventing exhaustion of engineered (e.g., chimeric antigen receptor (CAR) T cells) as well as non-engineered T cells thereby enhancing T cell function (e.g., activity against cancer or infectious disease).
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV
Fusion protein of anthrax toxin receptor cmg2 and human serum albumin
ActiveCN105237640BImprove in vivo activityHigh affinityFungiPeptide preparation methodsAnthrax toxin receptorsAnthrax Toxin Receptor 1
The invention discloses a fused protein. The first part of the fused protein is recombinant anthrax toxin receptor CMG2, the second part is recombinant human serum albumin, the first part and the second part are connected by a linker peptide, the half-life in vivo of the fused protein is increased by nearly 20 times compared with the recombinant anthrax toxin receptor CMG2. Also, the fused protein has very good in vivo activity, and can fully protect toxin attacked experimental animals.
Owner:INST OF BIOENG ACAD OF MILITARY MEDICAL SCI OF THE CHINESE
A kind of Escherichia coli strain for producing active short peptide
ActiveCN104789513BImprove in vivo activityLow costBacteriaBacteria material medical ingredientsMicroorganismIn vivo
The invention discloses an Escherichia coli strain for preparing active short peptides, the strain is Escherichia coli; the preservation name is Escherichia coli; it is preserved in CGMCC, General Microorganism Center of China Microbiological Culture Preservation Management Committee, and the preservation address is Chaoyang, Beijing No. 3, No. 1 Yard, Beichen West Road, District; date of deposit: October 24, 2014; deposit number: CGMCCNo.9842. The Escherichia coli bacterial agent prepared by the Escherichia coli described in the present invention. The present invention is an Escherichia coli strain capable of producing active short peptides with high in vivo activity and low cost.
Owner:YANGZHOU UNIV
Β-carboline, dihydro-β-carboline and tetrahydro-β-carboline alkaloid derivatives and preparation methods same and use in aspects of preventing and treating plant viruses, fungicides and insecticides
ActiveUS10208033B2Excellent activity against plant virusHigh activityBiocideOrganic chemistryFungicideMedicine
The present invention relates to β-carboline, dihydro-β-carboline and tetrahydro-β-carboline alkaloid derivatives (I) and a method for preparing same and the use in the aspects of preventing and treating plant viruses, fungicides and insecticides. For the meaning of each group in formula (I) see the description. The β-carboline, dihydro-β-carboline and tetrahydro-β-carboline alkaloid derivatives of the present invention show a particularly ourstanding anti-plant virus activity, and also have fungicidal and insecticidal activities.
Owner:NANKAI UNIV +1
Oleanolic acid and ursolic acid in the preparation of modulating vitamin D 3 Use in drugs that metabolize enzyme activity
ActiveCN109745330BImprove the level ofPromote Calcium BalanceOrganic active ingredientsMetabolism disorderBone densityMetabolic enzymes
Owner:THE HONG KONG POLYTECHNIC UNIV SHENZHEN RES INST
Hasylated polypeptides, especially hasylated erythropoietin
InactiveCN101580547BImprove biostabilityImprove biological activityCosmetic preparationsPowder deliveryCarbohydrate moietyThioether
Owner:FRESENIUS KABI DEUT GMBH
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com